FCCC LOGO Faculty Publications
Kozloff MF , Martin LP , Krzakowski M , Samuel TA , Rado TA , Arriola E , Carpeno JD , Herbst RS , Tarazi J , Kim S , Rosbrook B , Tortorici M , Olszanski AJ , Cohen RB
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
British Journal of Cancer. 2012 Oct;107(8) :1277-1285
PMID: WOS:000309963100012    PMCID: PMC3494447   
Back to previous list
Abstract
BACKGROUND: This phase I dose-finding trial evaluated safety, efficacy and pharmacokinetics of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, combined with platinum doublets in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumours. METHODS: In all, 49 patients received axitinib 5mg twice daily (b.i.d.) with paclitaxel/carboplatin or gemcitabine/cisplatin in 3-week cycles. Following determination of the maximum tolerated dose, a squamous cell NSCLC expansion cohort was enroled and received axitinib 5mg b.i.d. with paclitaxel/carboplatin. RESULTS: Two patients experienced dose-limiting toxicities: febrile neutropenia (n = 1) in the paclitaxel/carboplatin cohort and fatigue (n = 1) in the gemcitabine/cisplatin cohort. Common nonhaematologic treatment-related adverse events were hypertension (36.7%), diarrhoea (34.7%) and fatigue (28.6%). No grade >= 3 haemoptysis occurred among 12 patients with squamous cell NSCLC. The objective response rate was 37.0% for patients receiving axitinib/paclitaxel/carboplatin (n = 27) and 23.8% for patients receiving axitinib/gemcitabine/cisplatin (n = 21). Pharmacokinetics of axitinib and chemotherapeutic agents were similar when administered alone or in combination. CONCLUSION: Axitinib 5mg b.i.d. may be combined with standard paclitaxel/carboplatin or gemcitabine/cisplatin regimens without evidence of overt drug-drug interactions. Both combinations demonstrated clinical efficacy and were well tolerated. British Journal of Cancer (2012) 107, 1277-1285. doi:10.1038/bjc.2012.406 www.bjcancer.com Published online 18 September 2012 (C) 2012 Cancer Research UK
Notes
Kozloff, M. F. Martin, L. P. Krzakowski, M. Samuel, T. A. Rado, T. A. Arriola, E. De Castro Carpeno, J. Herbst, R. S. Tarazi, J. Kim, S. Rosbrook, B. Tortorici, M. Olszanski, A. J. Cohen, R. B. Pfizer Inc.; National Institutes of Health [P30 CA006927] This study was sponsored by Pfizer Inc. Support was provided in part by National Institutes of Health grant P30 CA006927 to the Fox Chase Cancer Center. We thank the patients who participated in this study and the physicians who referred them, as well as the study coordinators and data managers, Shelley Mayfield and Carol Martins at Pfizer Inc. for support of the study conduct, and Gamal ElSawah, Pfizer Medical Affairs, for his review of the manuscript. Medical writing support was provided by Joanna Bloom, of UBC Scientific Solutions (Southport, CT, USA) and Christine Arris at ACUMED (Tytherington, UK) and was funded by Pfizer Inc. 38 Nature publishing group London 022mi